Preliminary results of posterior capsule opacification following cataract surgery with implantation of the MICS-IOL L313
Session Details
Session Title: Posterior Capsule Opacification
Session Date/Time: Sunday 11/09/2016 | 08:30-10:00
Paper Time: 09:30
Venue: Hall C2
First Author: : H.Höh GERMANY
Co Author(s): : U. Holland C. Stylianides
Abstract Details
Purpose:
To collect intra- and postoperative data and evaluate the rate of posterior capsule opacification (PCO) following implantation of the MICS-IOL L313.
Setting:
Monocenter retrospective study at the Department of Ophthalmology of Dietrich-Bonhoeffer Klinikum in Neubrandenburg, Teaching Hospital of Ernst-Moritz-Arndt University Greifswald, Germany
Methods:
The data of 5.564 eyes, who had cataract surgery in our Hospital Outpatient Center between Sept. 2009 and Dec. 2013 with implantation of the MICS IOL L313 (Oculentis GmbH, Berlin, Germany) were collected between May 2013 and March 2016. Only the data of patients with their written informed consent were included. It was approved by the Ethics Committee of the University of Greifswald, Germany.
Evaluation was performed using Kaplan-Meier-Statistics with STATISTICA (StatSoft, Hamburg, Germany).
We could use the data sets of 2.171 eyes for an interim evaluation. Patients with posterior capsule tear were excluded.
Results:
Mean age of all patients at the time of surgery was 73,76 ± 9,06 (range 5 to 101, n=5.564). 59,16 % of the patients are female. The proportion of return of patients surveys until now is 36,7 %. Based on 2.171 data sets the rate of PCO was 4,5 % after 365 days, 7,3 % after 730 days, 13,3 % after 1460 days and 13,8% after 2190 days.
Conclusions:
After 850 days the 9,9% PCO rate of the L313 IOL is lower than the PCO rate of ThinLens (33,33%), of CareFlex (32,56%), of AcriSmart (20,0%) and of AcriFlex (11,36%).
Financial Disclosure:
... research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented
